Pharmacy Brokerage Services / Confidential Index / PBS-0417
Live sell-side mandate
A turnkey sterile facility that can't be rebuilt in a hurry.
A confidential opportunity to acquire a fully built-out cGMP 503B sterile compounding facility in Southern California — constructed 2015–2018, FDA-inspected in 2019, and offered turnkey. Replicating it would cost tens of millions and years of qualification. Identity and full detail are released to qualified buyers under a mutual non-disclosure agreement.
The opportunity
Built, equipped, inspected — and idle.
PBS-0417 is a non-operating cGMP sterile compounding facility in Southern California, purpose-built between 2015 and 2018 and FDA-inspected in 2019. It ran roughly a year of sterile production before pausing, and is offered fully built-out and equipped — ready to restart or convert.
The value is in what is already standing: three ISO 7 cleanroom suites, a 1,000-litre-per-hour Water-for-Injection system, and a documented FDA inspection history. It is positioned for financial sponsors and for strategic buyers — hospitals expanding into 503B, or pharmacies adding sterile and 503A capacity.
The replacement-cost case
You can't reproduce this quickly — or cheaply.
Offered turnkey — the buildout, equipment, and inspection history already exist. The premium a buyer avoids is measured in years, not just dollars.
What you're acquiring
The asset behind the thesis.
Physical and regulatory infrastructure that takes years to assemble — already in place.
Three ISO 7 suites
Cleanroom capacity purpose-built for sterile 503B production.
Water-for-Injection system
A 1,000 L/hr WFI system — among the hardest utilities to build and qualify.
cGMP construction
Purpose-built 2015–2018 to current good manufacturing practice standards.
FDA inspection history
Inspected in 2019 — a documented federal regulatory footprint.
503B outsourcing pathway
Positioned for outsourcing-facility sterile production at scale.
Turnkey & non-operating
Built and equipped, ready to restart or convert — no ground-up build.
At a glance
The blind-teaser snapshot.
Released under NDA
Entity name and address, equipment schedules, real-estate and lease terms, inspection documentation, and the full confidential information memorandum are shared only with qualified buyers under a mutual non-disclosure agreement.
Mandate PBS-0417
Request the confidential memorandum.
Qualified buyers receive the full CIM — facility detail, equipment, and the replacement-cost analysis — under a mutual NDA. Start with a confidential conversation.
Request the CIM under NDA